Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00032201 · ClinicalTrials.gov registry record
Cell Lines From High-Risk Breast Tissue
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 43
- Enrollment target
NCT00032201: Completed study, sponsored by National Cancer Institute (NCI).
NCT00032201 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 43 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00032201 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 43 participants
- Enrollment target
Study Summary
Background: * Many risk factors for breast cancer have been identified, including family history, endocrine background, changes in breast tissue, cancer in one breast, radiation exposure, obesity and others. There is a spectrum of tissue changes seen in cancerous and pre-cancerous breast tissue. * A cell line is a collection of cells that are grown in the laboratory from an original tissue specimen. Cell lines developed from high-risk breast tissue allow researchers to perform metabolic and molecular studies of breast cells over time. Objective: To establish a repository (facility in which tissue samples can be preserved and stored for many years) of cell lines from high-risk breast tissue to allow researchers to learn more about changes in breast cells that may cause them to develop into breast cancer. Eligibility: Women between 20 and 80 years of age who: * Have an increased risk of breast cancer because they are members of a high-risk breast or ovarian cancer family. * Have had breast cancer in one or both breasts. * Have had radiation for lymphoma before the age of 30. * Have a mutation in a breast cancer susceptibility gene, but whose family history is not known. * Are not at increased risk of breast cancer. Design: * A small piece of breast tissue will be obtained from about 10 women without an identified risk of breast cancer and up to 100 women at high risk of developing breast cancer. * Cell lines will be developed from each high-risk category. * The cell lines and tissues will be used to establish a repository of high-risk breast cell lines and breast tissues that can be used to study how the cells develop into breast cancer.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2002-03-06 |
| Est. Completion | 2014-12-03 |
What the finished NCT00032201 record still lists
NCT00032201 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 43 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00032201 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00032201 about?
NCT00032201 is a clinical study titled "Cell Lines From High-Risk Breast Tissue". Background: * Many risk factors for breast cancer have been identified, including family history, endocrine background, changes in breast tissue, cancer in one breast, radiation exposure, obesity and others. There is a spectrum of tissue changes seen in cancerous and pre-cancerous breast tissue. * ...
What is the current status of trial NCT00032201?
This trial is currently completed. The enrollment target is 43 participants. The study started on 2002-03-06. Estimated completion is 2014-12-03.
Who is sponsoring clinical trial NCT00032201?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI